Company: Neurotec Pharma
Drug Type: Small Molecule
Conditions: ALS, multiple sclerosis, stroke
Mechanism Type: Immunomodulation
Mechanism: NT-K0-003 is a small molecule modulator of microglial activity that confers neuroprotection according to preclinical studies. The compound, also known as diazoxide, is a K-ATP potassium channel activator that may reduce inflammation by blocking microglial activation.
U.S. Status for ALS: Preclinical
 Diazoxide For Use In The Treatment Of Amyotrophic Lateral Sclerosis (ALS). FreePatentsOnline, 6 June 2013. Accessed 11 March, 2016 from http://www.freepatentsonline.com/y2013/0143873.html
 Effects of diazoxide in multiple sclerosis: A randomized, double-blind phase 2 clinical trial. Villoslada, P. et al. Neurol Neuroimmunol Neuroinflamm. 2015 Sep 10;2(5):e147.
 A Phase IIa Study of NT-KO-003 for Multiple Sclerosis ClinicalTrials.gov, 14 March, 2014. Accessed 11 March 2016 from https://clinicaltrials.gov/ct2/show/NCT01428726
Last updated March 8th, 2019